ОБ ЭТОМ ЭПИЗОДЕ

английский
США

РАСШИФРОВКА 🔗

ПОИСК ПРОШЛЫХ ЭПИЗОДОВ

Искать прошлые эпизоды Pharma and BioTech Daily.

ДРУГИЕ ЭПИЗОДЫ В ЭТОМ ПОДКАсте

Full Lp(a)HORIZON results at AHA show Novartis' pelacarsen cut Lp(a) by 78 percent with no cardiovascular benefit, as the FDA heads into a crowded month of decisions on ivonescimab, deramiocel and povetacicept. Also: Mineralys' lorundrostat holds its effect at 48 weeks, Sarepta's new…
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling stories that highlight the dynamic nature of the industry, marked by strategic acquisitions, groundbreaking research, and …
Vir Biotechnology reports a pivotal Phase 3 win in chronic hepatitis delta, and argenx agrees to buy Unnatural Products for up to 1.15 billion dollars to add oral macrocyclic peptides. Also: TG Therapeutics raises Briumvi guidance, Xenon's azetukalner filing and X-NOVA2 timing, and Atea's…
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most compelling stories shaping the industry. Let's begin with GSK's bold move to expand its biologics capabiliti…
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of exciting advancements and strategic shifts reshaping the landscape of drug development and patient care. A noteworthy collaboration …
Отказ от ответственности: Подкаст и иллюстрации, встроенные в эту страницу, взяты из Pharma and BioTech News, который является собственностью его владельца и не связан или не одобрен Listen Notes, Inc.